Myasthenia gravis natural history, complications and prognosis

Jump to navigation Jump to search

Myasthenia gravis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myasthenia Gravis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myasthenia gravis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myasthenia gravis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myasthenia gravis natural history, complications and prognosis

CDC on Myasthenia gravis natural history, complications and prognosis

Myasthenia gravis natural history, complications and prognosis in the news

Blogs on Myasthenia gravis natural history, complications and prognosis

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myasthenia gravis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Keanu Ngo[2]

Overview

Natural history: The age at onset of AChR-antibody-positive MG is bimodal, divided at age 50 into early-onset MG ( < 50 years, female-predominant, often associated with thymic hyperplasia) and late-onset MG ( ≥ 50 years, male-predominant). Approximately 85% of patients present with ocular symptoms, most commonly ptosis and diplopia. About 15% remain purely ocular, while the remainder develop generalized disease, with most generalization occurring within the first 2 years and occurring more frequently in AChR-antibody-positive patients. The disease course is largely established early, with approximately 77–82% of patients reaching maximal weakness within the first 2–3 years.[1][2][3]

Complications: The major acute complication is myasthenic crisis—respiratory failure caused by respiratory or bulbar muscle weakness requiring ventilatory support—which affects approximately 15% of patients and occurs predominantly during the early years of disease.[1] Long-term morbidity also arises from chronic immunosuppressive and immunomodulatory therapy, including corticosteroids and nonsteroidal immunosuppressants, as well as from acute treatments such as plasma exchange and intravenous immunoglobulin.[4]

Prognosis: Prognosis in the modern treatment era is generally favorable. More than 60% of patients with recently diagnosed generalized MG eventually achieve long-term freedom from symptoms or minimal manifestation status, with most clinical improvement occurring within the first 2 years.[5] Disease-related mortality has fallen substantially—from roughly 70% in the pre-treatment era to approximately 2% in modern series—although mortality in myasthenic crisis remains higher, generally < 5% in contemporary U.S. cohorts and higher in some international series and older patients.[6][7] Favorable prognostic factors include younger age at onset, milder disease and shorter disease duration at diagnosis, seronegativity, thymic hyperplasia, and early thymectomy when indicated; the effect of sex on outcome is inconsistent across cohorts.[3][8][9] Unfavorable factors include onset at ≥ 50 years, severe bulbar disease, and thymoma.[3]

References

  1. ↑ 1.0 1.1 Punga AR; Maddison P; Heckmann JM; Guptill JT; Evoli A (2022). "Epidemiology, Diagnostics, and Biomarkers of Autoimmune Neuromuscular Junction Disorders". The Lancet Neurology. 21 (2): 176–188. doi:10.1016/S1474-4422(21)00297-0. PMID 35065040 Check |pmid= value (help).
  2. ↑ Gilhus NE (2016). "Myasthenia Gravis". The New England Journal of Medicine. 375 (26): 2570–2581. doi:10.1056/NEJMra1602678.
  3. ↑ 3.0 3.1 3.2 Alkhawajah NM; Oger J (2013). "Late-onset myasthenia gravis: A review when incidence in older adults keeps increasing". Muscle & Nerve. 48 (5): 705–710. doi:10.1002/mus.23964.
  4. ↑ Gilhus NE; Verschuuren JJ (2015). "Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies". The Lancet Neurology. 14 (10): 1023–1036. doi:10.1016/S1474-4422(15)00145-3.
  5. ↑ Tomschik M; Hilger E; Rath J; et al. (2020). "Subgroup Stratification and Outcome in Recently Diagnosed Generalized Myasthenia Gravis". Neurology. 95 (10): e1426–e1436. doi:10.1212/WNL.0000000000010209.
  6. ↑ Verschuuren JJ; Palace J; Murai H; et al. (2022). "Advances and Ongoing Research in the Treatment of Autoimmune Neuromuscular Junction Disorders". The Lancet Neurology. 21 (2): 189–202. doi:10.1016/S1474-4422(21)00463-4. PMID 35065041 Check |pmid= value (help).
  7. ↑ Claytor B; Cho SM; Li Y (2023). "Myasthenic crisis". Muscle & Nerve. 68 (1): 8–19. doi:10.1002/mus.27832.
  8. ↑ Baggi F; Andreetta F; Maggi L; et al. (2013). "Complete Stable Remission and Autoantibody Specificity in Myasthenia Gravis". Neurology. 80 (2): 188–195. doi:10.1212/WNL.0b013e31827b907b.
  9. ↑ Sanders DB; Lutz MW; Raja SM; et al. (2023). "The Duke Myasthenia Gravis Clinic Registry: II. Analysis of outcomes". Muscle & Nerve. 67 (4): 291–296. doi:10.1002/mus.27794.

Natural History, Complications, and Prognosis

Natural history

The clinical course of myasthenia gravis (MG) is generally established early. Approximately 77–82% of patients reach maximal weakness within the first 2–3 years after onset. Thereafter, patients may improve, remain stable, or enter remission. Fluctuating, fatigable weakness remains characteristic throughout the disease course, and symptomatic relapses may occur even after prolonged periods of clinical stability.[1][2][3]

Ocular onset and generalization

Ocular symptoms are common at MG onset. Approximately 15–25% of patients remain with purely ocular MG, whereas a substantial proportion subsequently develop generalized disease.[4]

A systematic review and meta-analysis estimated that a pooled 39% (95% CI 32–47%, low certainty) of patients with ocular MG convert to secondary generalized disease, with most generalization occurring within the first 2 years.[4] Reported generalization rates vary among cohorts. Punga et al. reported that 17–50% of patients generalize within 6–12 months and 61–85% within 2 years, with a smaller proportion generalizing thereafter.[2] AChR-seropositive patients may generalize substantially earlier than seronegative patients, with one cohort reporting median times of approximately 5 versus 21 months.[5]

Risk factors associated with generalization include AChR-antibody positivity, thymic hyperplasia, bilateral ptosis, and abnormal repetitive nerve stimulation.[6] In juvenile MG specifically, pubertal onset is a strong predictor of subsequent generalization (OR approximately 5), with a median conversion time of approximately 2.75 years.[7]

Patients who remain ocular for several years have a lower subsequent risk of generalization, but a stable ocular presentation does not completely exclude later generalized disease.[2][5]

Subgroup-specific course

Clinical course and prognosis vary by serologic and clinical subgroup.[8]

  • MuSK-MG is characterized by prominent bulbar, facial, neck, and respiratory weakness and a higher risk of myasthenic crisis. Ocular weakness may diminish over time while bulbar and generalized weakness persists. Response to acetylcholinesterase inhibitors may be limited.[9][8]
  • Late-onset AChR-MG and thymoma-associated MG are associated with higher crisis and mortality risk.[1][2]
  • Differences in disease severity between antibody subgroups may diminish over longer-term follow-up with consistent immunosuppressive treatment.[10]

Complications

Myasthenic crisis

Myasthenic crisis is the major acute complication of MG, characterized by respiratory failure requiring noninvasive or invasive ventilatory support due to respiratory muscle weakness and/or bulbar-related upper-airway compromise. Approximately 15–20% of patients experience myasthenic crisis, with risk concentrated particularly during the first several years of disease.[11]

Myasthenic crisis affects up to 20% of patients at least once during their lifetime. The annual incidence is approximately 2.5% across patients with MG, and the mean lead time from diagnosis to first crisis is approximately 8–12 months.[12][11]

Common precipitating factors include:

  • Respiratory infection, the most common identified trigger
  • Aspiration
  • Surgery, including thymectomy
  • Pregnancy and childbirth
  • Rapid reduction of immunosuppressive therapy
  • Initiation of corticosteroids
  • Medications known to worsen neuromuscular transmission, including fluoroquinolones, aminoglycosides, tetracyclines, telithromycin, magnesium, quinine, and botulinum toxin[2][11]

No precipitating factor is identified in a substantial proportion of crises.[11]

Patients at higher risk include those with prior crisis, severe oropharyngeal disease, MuSK antibodies, thymoma, and late-onset AChR-positive MG.[11]

Warning features include worsening bulbar dysfunction, dysphagia or choking, dyspnea or tachypnea, orthopnea, accessory-muscle use, paradoxical breathing, and difficulty managing secretions.[2]

Management requires ICU-level monitoring and, when indicated, ventilatory support and rapid immunomodulatory rescue therapy with plasma exchange or intravenous immunoglobulin. Detailed treatment selection and dosing belong in Myasthenia gravis medical therapy.[13]

Most patients are weaned from ventilatory support within about 1 month. Reported crisis mortality varies by setting: contemporary U.S. inpatient cohorts report approximately 2–5%, whereas international series from Germany and China report approximately 12–15%, and mortality among hospitalized patients has been cited as high as 12–18%. Mortality is strongly age-dependent—approaching zero below age 40 but rising to roughly 18% among patients aged 65–84 years and nearly 50% among those aged ≥85 years for 30-day post-discharge mortality after crisis admission in U.S. data—and is driven largely by comorbidity.[11][14][2][15]

Approximately one-third of crisis survivors experience a subsequent crisis. Prolonged intubation lasting more than 2 weeks is associated with greater functional dependence at discharge, with dependence reported in approximately 77% versus 36% of patients with shorter ventilation. Crisis itself does not appear to worsen the long-term MG prognosis.[11]

Cholinergic crisis

Cholinergic crisis caused by excessive acetylcholinesterase inhibitor exposure is now uncommon but remains a potential cause of acute worsening. Excess cholinergic activity can also increase airway secretions and complicate respiratory management.[13]

Treatment-related morbidity is an important component of the long-term MG disease burden.

  • Corticosteroids: initiation may cause transient worsening of weakness. Longer-term complications include weight gain, hyperglycemia, hypertension, osteoporosis, cataract, glaucoma, skin fragility, gastrointestinal complications, mood or cognitive effects, and cardiovascular risk.[8]
  • Azathioprine: myelosuppression, hepatotoxicity, macrocytosis, and potential long-term malignancy risk. TPMT assessment is used to identify patients at increased risk of severe myelotoxicity.
  • Complement inhibitors: eculizumab, ravulizumab, and zilucoplan increase susceptibility to meningococcal infection; appropriate vaccination is required before complement inhibition according to treatment guidance.[16]
  • FcRn inhibitors: efgartigimod, rozanolixizumab, and nipocalimab reduce circulating IgG and may increase infection risk; headache is also reported with this drug class.[16]
  • Intravenous immunoglobulin: potential complications include headache, aseptic meningitis, thrombosis, renal injury, and hypersensitivity reactions.[13]
  • Plasma exchange: potential complications include vascular-access infection, hemodynamic instability, and thrombosis.[13]

Prognosis

Overall prognosis has improved substantially in the modern treatment era. With current symptomatic, immunosuppressive, and supportive therapy, most patients achieve substantial improvement, and steady disease progression is uncommon. Life expectancy is generally close to that of the general population, although risk varies substantially by age, disease subgroup, comorbidity, and complications.[8]

Mortality has declined dramatically compared with the pre-intensive-care era. Modern generalized-MG cohorts demonstrate substantially better long-term outcomes, with more than 60% eventually achieving long-term freedom from symptoms including minimal manifestation status; most improvement occurs during the first 2 years of follow-up.[3][17]

Approximately 10–15% of patients remain treatment-refractory in modern cohorts.[3]

Complete stable remission

Complete stable remission (CSR) is uncommon. Contemporary patient-reported data suggest that fewer than 10% achieve complete stable remission, defined as absence of MG symptoms without medication.[18]

An earlier Italian cohort reported a cumulative CSR probability of approximately 21% by 10 years, with greater likelihood associated with younger onset, milder clinical stage, and shorter disease duration at diagnosis.[19]

Prognostic factors

More favorable factors Less favorable factors
Younger age at onset Age ≥50 years at onset
Milder disease at onset Severe bulbar disease at onset
Seronegativity Thymoma
Shorter disease duration at diagnosis Prolonged intubation during crisis
Thymic hyperplasia Significant comorbidity
Radical thymectomy when indicated Late-onset AChR-positive MG

These factors are associations rather than absolute predictors of individual outcome.[1][8][2][19]

Cancer-related mortality is increased in thymoma-associated MG, and mortality generally increases with older age and comorbidity.[2]

High-yield clinical points

  • The disease course is generally established early, with approximately 80% of patients reaching maximal weakness within 2–3 years.[1]
  • A pooled 39% of patients with ocular MG develop secondary generalized disease, with most conversions occurring within the first 2 years.[4]
  • Myasthenic crisis affects up to 20% of patients during their lifetime, with an annual incidence of approximately 2.5%.[12][11]
  • Myasthenic crisis is commonly preceded by worsening bulbar or respiratory symptoms and is frequently triggered by infection, aspiration, surgery, medication exposure, or treatment changes.[2][11]
  • Crisis mortality varies substantially by population and age; older patients and those with significant comorbidity have the highest mortality risk.[14][15]
  • MuSK-MG, thymoma-associated MG, and late-onset AChR-positive MG are associated with greater crisis risk.[11][2]
  • Corticosteroid initiation can transiently worsen weakness and is a recognized precipitant of crisis.[13]
  • Complete stable remission is uncommon; long-term minimal manifestation status or substantial improvement is a more realistic treatment outcome for many patients.[18]

Common pitfalls

  • Assuming stable ocular disease permanently excludes subsequent generalization.
  • Attributing every episode of acute worsening to cholinergic crisis; true cholinergic crisis is now uncommon.[13]
  • Overlooking preventable crisis triggers, particularly respiratory infection, aspiration, potentially aggravating medications, and corticosteroid initiation.[2][11]
  • Failing to recognize the distinct clinical and prognostic profile of MuSK-MG.[9]
  • Forgetting the meningococcal infection risk associated with complement inhibitors.[16]

References

  1. ↑ 1.0 1.1 1.2 1.3 Alkhawajah NM; Oger J (2013). "Late-onset myasthenia gravis: A review when incidence in older adults keeps increasing". Muscle & Nerve. 48 (5): 705–710. doi:10.1002/mus.23964.
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 Punga AR; Maddison P; Heckmann JM; Guptill JT; Evoli A (2022). "Epidemiology, Diagnostics, and Biomarkers of Autoimmune Neuromuscular Junction Disorders". The Lancet Neurology. 21 (2): 176–188. doi:10.1016/S1474-4422(21)00297-0. PMID 35065040 Check |pmid= value (help).
  3. ↑ 3.0 3.1 3.2 Tomschik M; Hilger E; Rath J; et al. (2020). "Subgroup Stratification and Outcome in Recently Diagnosed Generalized Myasthenia Gravis". Neurology. 95 (10): e1426–e1436. doi:10.1212/WNL.0000000000010209. PMID 32641537 Check |pmid= value (help).
  4. ↑ 4.0 4.1 4.2 Fang CEH; Bokre D; Wong SH (2023). "Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: A Systematic Review and Meta-Analysis". Neurology. 101 (16): e1594–e1605. doi:10.1212/WNL.0000000000207642. PMID 37643888 Check |pmid= value (help).
  5. ↑ 5.0 5.1 Kamarajah SK; Sadalage G; Palmer J; et al. (2018). "Ocular presentation of myasthenia gravis: A natural history cohort". Muscle & Nerve. 57 (4): 622–627. doi:10.1002/mus.25971.
  6. ↑ Menon D; Alharbi M; Katzberg HD; et al. (2024). "Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study". Neurology. 103 (4): e209722. doi:10.1212/WNL.0000000000209722.
  7. ↑ Huang X; Yu ZH; Cui Y; et al. (2025). "Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis". Neurology. 105 (12): e214428. doi:10.1212/WNL.0000000000214428.
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Gilhus NE; Verschuuren JJ (2015). "Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies". The Lancet Neurology. 14 (10): 1023–1036. doi:10.1016/S1474-4422(15)00145-3. PMID 26376969.
  9. ↑ 9.0 9.1 Huijbers MG; Marx A; Plomp JJ; Le Panse R; Phillips WD (2022). "Advances in the Understanding of Disease Mechanisms of Autoimmune Neuromuscular Junction Disorders". The Lancet Neurology. 21 (2): 163–175. doi:10.1016/S1474-4422(21)00357-4. PMID 35065039 Check |pmid= value (help).
  10. ↑ Andersen JB; Gilhus NE; Sanders DB (2016). "Factors affecting outcome in myasthenia gravis". Muscle & Nerve. 54 (6): 1041–1049. doi:10.1002/mus.25205.
  11. ↑ 11.00 11.01 11.02 11.03 11.04 11.05 11.06 11.07 11.08 11.09 11.10 Claytor B; Cho SM; Li Y (2023). "Myasthenic crisis". Muscle & Nerve. 68 (1): 8–19. doi:10.1002/mus.27832.
  12. ↑ 12.0 12.1 Narayanaswami P; Mantegazza R; Barnett-Tapia C; et al. (2026). "Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method". Neurology: Clinical Practice. 16 (4): e200644. doi:10.1212/CPJ.0000000000200644.
  13. ↑ 13.0 13.1 13.2 13.3 13.4 13.5 Sanders DB; Wolfe GI; Benatar M; et al. (2016). "International Consensus Guidance for Management of Myasthenia Gravis: Executive Summary". Neurology. 87 (4): 419–425. doi:10.1212/WNL.0000000000002790. PMID 27358333.
  14. ↑ 14.0 14.1 Habib AA; Sacks N; Cool C; et al. (2024). "Hospitalizations and Mortality From Myasthenia Gravis: Trends From 2 US National Datasets". Neurology. 102 (2): e207863. doi:10.1212/WNL.0000000000207863.
  15. ↑ 15.0 15.1 Huan X; Chen R; Jin L; et al. (2026). "1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China". European Journal of Neurology. 33 (2): e70513. doi:10.1111/ene.70513.
  16. ↑ 16.0 16.1 16.2 Menon D; Bril V (2022). "Pharmacotherapy of Generalized Myasthenia Gravis With Special Emphasis on Newer Biologicals". Drugs. 82 (8): 865–887. doi:10.1007/s40265-022-01726-y. PMID 35639288 Check |pmid= value (help).
  17. ↑ Verschuuren JJ; Palace J; Murai H; et al. (2022). "Advances and Ongoing Research in the Treatment of Autoimmune Neuromuscular Junction Disorders". The Lancet Neurology. 21 (2): 189–202. doi:10.1016/S1474-4422(21)00463-4. PMID 35065041 Check |pmid= value (help).
  18. ↑ 18.0 18.1 Lee I; Leach JM; Aban I; et al. (2022). "One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry". Muscle & Nerve. 66 (4): 411–420. doi:10.1002/mus.27659.
  19. ↑ 19.0 19.1 Baggi F; Andreetta F; Maggi L; et al. (2013). "Complete Stable Remission and Autoantibody Specificity in Myasthenia Gravis". Neurology. 80 (2): 188–195. doi:10.1212/WNL.0b013e31827b907b. PMID 23255823.

References


Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Myasthenia_gravis_natural_history,_complications_and_prognosis&oldid=1745854"